echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 40 billion market waves again 5 big PPI injections by internal and external clamping!

    40 billion market waves again 5 big PPI injections by internal and external clamping!

    • Last Update: 2021-02-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    recently, Takeda's class 5.1 new drug Fuma acid Vonora Zan tablets were approved for listing by the State Drug Administration. The drug is a new mechanism of acid suppressant, its rapid acid suppression ability to proton pump inhibitors to bring market threats. Not long ago, Wuhan City will be 5 PPI injections into the volume of procurement, drug prices will be "diving." In 2018, top10 products for terminal treatment of stomach acid secretion-related diseases in China's public medical institutions are proton pump inhibitors, with AstraZeneone, Osaikang, Yangzijiang and Zhengda Tianqing occupying the main market share of related varieties, according to Minanet data.The acid suppressant "rookie" is coming! PPI enemymeters net data show that recently Takeda's 5.1 class of new drug Fuma acid Vonorazan tablets approved by the State Drug Administration for the treatment of refractory esophedritis. Fumaric acid Vonorazan tablets are a new mechanism for the anti-acid drug, potassium ion competitive acid blocker (P-CAB), which was first approved for sale in Japan on December 26, 2014. On March 20, 2018, Takeda's application for the listing of Fumaric Vonora Zan was accepted by the CDE contractor, and the domestic listing was officially approved on December 18, 2019.Reflowal esoitis is an inflammatory lesions of the esoesosis caused by the reflow of gastrointestinal contents into the esoesoin, and is one of the most common diseases in the digestive system. In recent years, its incidence rate has been increasing year by year. According to statistics, about 1/3 of the population has different degrees of the disease, of which more than 5% of the patients have serious interference in their lives.Proton pump inhibitor (PPI) is currently the drug of choice for the treatment of reflowal esophagealitis, and its mechanism of action is to block the gastric wall proton pump to drive the exchange of hydrogen ions in cells with potassium ions in small tubes, thus preventing the secretion of stomach acid. Compared with PPI, P-CAB can quickly inhibit the secretion of stomach acid by binding to H-/K-ATP enzyme in a competitive way and reversible way of potassium ions, and the first dose can achieve maximum acid suppression effect.5 PPI injections will cut prices to grab the market?Recently, Wuhan Pharmaceutical Joint Procurement Office announced the first batch of drugs in 2019 centralized belt procurement catalog, 45 varieties will carry out strip procurement, mainly related to the drug category of proton pump inhibitors, antibacterial drugs, insulin and so on. Among them, the proton pump inhibitors were selected in five varieties, namely, Esomerazole, Omerazole, Lansolazi, Reberazole, and Vitolazo.In terms of procurement volume, omeprazole, lanso lazi, and vitolazole agreed to purchase more than 1 million units, and the agreed purchase volume of 3 specifications of pythonazole powder needles totaled 7177113 units. According to the Regulations on the Purchase of the First Batch of Drugs in Wuhan city in 2019, the quotation of enterprises shall not be higher than the lowest price of the national provincial-level network on December 1, 2019. According to the latest announcement, the official offer date is 9:00-13:00 on December 30, 2019. This means that PPI injections, which are included in the volume purchase, will be exchanged for substantial price reductions in exchange for the market.Osaikang, Yangzijiang, Zhengda sunny... Data from the internal and external -meter internal network show that in 2018, sales of end-use drugs for the treatment and gastric acid secretion-related diseases in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) amounted to 41.829 billion yuan, up 2.78 percent year-on-year.China's public medical institutions terminal treatment and gastric acid secretion-related diseases drug sales(10,000 yuanIn the treatment and stomach acid secretion-related diseases of the drug TOP10, the listed products are proton pump inhibitors, and sales are more than 1 billion yuan, injection of sodium vitolazole with 7,913 million yuan sales in the first place. In terms of sales growth rate, the growth rate of sodium reberazole for injection led by 80.68 percent, while the sales growth rate of three injections, namely lanso laazole for injection, sodium sodium for injection and sodium omeprazole for injection, declined.
    Data on top 10meters of end-use drugs for terminal treatment and stomach acid secretion-related diseases in China's public medical institutions in 2018 show that the total sales of five PPI injections purchased by Wuhan City in 2018 exceeded 23.6 billion yuan. Okonsai occupies the main market share of the three varieties of omeprazole, Lanso laazole and reberazole, AstraZeneone, Zhengda Tianqing occupies the main market share of Esomerazole, and Yangzijiang occupies the main market share of the three varieties.Wuhan city with the volume of procurement of PPI injection competition patternwith the acid suppressant "rookie" Vono razan approved for listing in China, as well as Wuhan's first batch of volume procurement varieties will be PPI injections into the market competition for proton pump inhibitors is becoming increasingly fierce, prices are also facing downswing pressure. Okonsai, Yangzijiang, Zhengda Tianqing who will take the volume of procurement in a large price reduction to keep the market? We'll see! (Mi net)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.